Zonisamide: Review of Recent Clinical Evidence for Treatment of Epilepsy

Shang Yeong Kwan, Yao Chung Chuang, Chin Wei Huang, Ta Cheng Chen, Shuo Bin Jou, Amitabh Dash

研究成果: Review article同行評審

13 引文 斯高帕斯(Scopus)

摘要

Zonisamide is an orally administered antiepileptic drug that was first approved for clinical use in Japan in 1989. Since then, it has been licensed in Korea for a broad spectrum of epilepsies in adults and children, and in the USA for adjunctive therapy of adults with partial seizures, and in Europe for monotherapy of adults with newly diagnosed partial seizures and adjunctive therapy of adults and adolescents and children aged ≥6 years with partial seizures with or without secondary generalization. Zonisamide is a benzisoxazole derivative with a unique chemical structure, predictable dose-dependent pharmacokinetics, and multiple complementary mechanisms of action. Treatment with zonisamide is well tolerated and is not known to be associated with clinically significant drug-drug interactions, including with oral contraceptives or other antiepileptic drugs. There have been >2 million patient-years of experience with zonisamide for treatment of epilepsy, and this drug has International League Against Epilepsy level A evidence for efficacy/effectiveness as initial monotherapy for adults with partial-onset seizures. This review presents the evidence for zonisamide across the spectrum of epilepsy, with emphasis on real-world clinical practice and special populations of patients (children, elderly patients, and women of childbearing age) who are likely to be treated in daily clinical practice.

原文English
頁(從 - 到)683-691
頁數9
期刊CNS Neuroscience and Therapeutics
21
發行號9
DOIs
出版狀態Published - 2015 九月 1

All Science Journal Classification (ASJC) codes

  • 藥理
  • 精神病學和心理健康
  • 生理學(醫學)
  • 藥學(醫學)

指紋

深入研究「Zonisamide: Review of Recent Clinical Evidence for Treatment of Epilepsy」主題。共同形成了獨特的指紋。

引用此